Salute e Benessere

VIRBAC - 2023 half-year results: publication postponed to end of September

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay Following the cyberattack that targeted us on June 19, exceptional measures were immediately taken to contain it and a crisis unit including experts dedicated to cybersecurity was set up to assess the impact on our systems and quickly organize the remediation operations necessary for the...
Nasdaq GlobeNewswire
22/08/2023

Transactions in connection with share buy-back program

Company announcement no. 41 - 2322 August 2023 Transactions in connection with share buy-back program On 3 August 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 38 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
22/08/2023

Robotic Dentistry Market worth $1.0 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48850788 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48850788 Browse in-depth TOC on "Robotic Dentistry Market" 150 - Tables 100 - Figures 200 - Pages Robotic Dentistry Market Scope: "During the forecast period, the standalone robot is expected to be the fastest growing segment of the robotic dentistry market." Under...
PR Newswire
22/08/2023

The AI in Clinical Trials Market is anticipated to grow at a CAGR of ~16% till…

Driven by the diverse advantages and ongoing advancements in AI, the demand for AI software and services in clinical trials has increased in the healthcare industry. As a result, clinical trial sponsors have started utilizing AI to streamline clinical trials and obtain desired patient outcomes, resulting in a more patient-centric, time and cost-effective, and easy to manage approach. Driven by the diverse advantages and ongoing advancements in AI, the demand for AI software and services in...
PR Newswire
22/08/2023

Central Venous Catheter Market to Reach $4.7 Billion, Globally, by 2032 at a…

A CVC (central venous catheter) is a flexible, long tube inserted by your provider into a vein in the neck, chest, arm, or groin. The tube leads to the vena cava (a large vein that drains into the heart). A CVC can be used to administer drugs, liquids, or blood for emergency treatment or long-term care. A CVC can also be used for blood draws. Common types of CVC are PICC lines or ports. A CVC (central venous catheter) is a flexible, long tube inserted by your provider into a vein in the neck,...
PR Newswire
22/08/2023

Alvotech to Report Financial Results for the First Half of 2023 on August 30…

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months of 2023, after U.S. markets close on Wednesday, August 30, 2023.Following the release, Alvotech will conduct a business update conference call for analysts on Thursday, August 31, 2023, at 8:00 am ET (12:00 pm GMT / 14:00 pm CET). Live audio of the conference call will...
Nasdaq GlobeNewswire
22/08/2023

Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" Designated…

SD-101 received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) covering the broad treatment of EB. In addition to the Rare Pediatric Disease designation, SD-101 was granted Orphan Drug designation from the FDA and the European Commission (EC) and was the first EB treatment to receive the FDA's Breakthrough Therapy designation. SD-101 received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) covering the broad treatment of...
PR Newswire
22/08/2023

Aurisco's Busy Business Development

Join our team at the above events to discuss your challenges in oligonucleotide, peptide and small molecule development. Join our team at the above events to discuss your challenges in oligonucleotide, peptide and small molecule development. Alessandro Ricci, President of Aurisco's US Operations, based inNew Yorksaid: "We recently passed another USFDA inspection and have great new products and differentiated technologies. Customers want to expand their collaborations with Aurisco, and...
PR Newswire
22/08/2023

Change in Orion Group Executive Management Board as of February 1st, 2024 –…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 22 August 2023 at 14.00 EEST Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President , People & CultureMs. Julia Machareyhas been appointed Senior Vice President of Orion Group's new People & Culture group-level function and member of the Executive Management Board of Orion Group as of February...
Nasdaq GlobeNewswire
22/08/2023

Revolutionizing Global Clinical Trials: Clario's Scientific Excellence and…

LEQEMBI® (lecanemab-irmb) is only the second FDA-approved therapy in a new generation of Alzheimer's disease (AD) treatments, providing a lifetime of hope for afflicted patients and their loved ones. Its clinical trial program required long-term technical and scientific support to ensure the most effective collection and analysis of data to demonstrate the drug's safety and efficacy for the FDA's accelerated approval. LEQEMBI ®(lecanemab-irmb) is only the second FDA-approved therapy in a new...
PR Newswire
22/08/2023

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses…

Non-clinical data previously showed that Novavax's COVID vaccine candidate induced functional immune responses for XBB.1.5, XBB.1.16 and XBB.2.3 variants, indicating a broad response that could potentially be applicable for forward-drift variants.3 Novavax is in the process of submitting applications for its XBB.1.5 COVID vaccine candidate to regulatory authorities globally. Non-clinical data previously showed that Novavax's COVID vaccine candidate induced functional immune responses for…
PR Newswire
22/08/2023

Ratchaphruek Hospital in Khon Kaen, Thailand Achieves GHA Accreditation with…

GHA's prestigious accreditation marks a significant milestone in Ratchaphruek Hospital's pursuit of excellence in medical travel services. The hospital's commitment to delivering exceptional patient experiences, combined with its focus on clinical outcomes and safety, sets it apart as a leading institution in the region. GHA's prestigious accreditation marks a significant milestone in Ratchaphruek Hospital's pursuit of excellence in medical travel services. The hospital's commitment to...
PR Newswire
22/08/2023

New study: ColdZyme breaks viral infection cycle - significantly reducing…

"We know from previous studies that ColdZyme blocks viruses from sticking. These new results, showing how ColdZyme breaks the infection cycle, could open new commercial opportunities for Enzymatica. We are expecting results from an in vivo study from the University of Kent within the coming month and anticipate that it will add further clinical insights", said Claus Egstrand, CEO of Enzymatica. The research group is working on a manuscript for publication, expected in 2023. It was…
PR Newswire
22/08/2023

BerGenBio announces clinical data presentations highlighting the activity of its…

Contacts Contacts Martin Olin CEO, BerGenBio ASAir@bergenbio.com Rune Skeie, CFO, BerGenBio ASArune.skeie@bergenbio.com Media Relations Jan Lilleby jl@lillebyfrisch.no+47 90 55 16 98 About BerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its...
PR Newswire
22/08/2023

'Positive results from PK study with cobitolimod' selected as one of the best…

The PK study results will be presented by principal investigator Professor Per Hellström on October 15 at 10:30 CET on Poster Stage 1, during the moderated poster session: "Medical therapy of IBD: Facts and challenges." The PK study results will be presented by principal investigator ProfessorPer HellströmonOctober 15at10:30 CETon Poster Stage 1, during the moderated poster session: "Medical therapy of IBD: Facts and challenges." Results from the PK study included PK data…
PR Newswire
22/08/2023

Berlin Heals Holding AG welcomes Dr. Felix Baader and Roland Diggelmann as new…

Dr. Felix Baadercommented: "I am honoured to be part of Berlin Heals' Board of Directors at this important stage. The company has a revolutionary product that will massively and sustainably improve the quality of life of many heart patients." Dr. Baader held various key positions in the healthcare and technology sectors over the last 30 years, including at Roche Diagnostics, Biotronik and Philips and today holds board mandates at Congenius, Valtronic Holding and Bibus Group AG, among…
PR Newswire
22/08/2023

Corsano Health launches Cuffless Blood Pressure

The CardioWatch 287-2 is a EU-MDR certified wireless remote monitoring intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, heart rate variability (R-R interval), respiration rate, activity, sleep, ECG, SpO2, Body Temperature and Blood Pressure. Data is transmitted wirelessly from the device via the application or gateway to a server or health cloud where it is stored and made available for further analysis. The CardioWatch 287-2…
PR Newswire
22/08/2023

Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides…

Oslo, 22August2023:Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its second quarter 2023 results today. “In the first half of this year, Ultimovacs has further advanced the broad evaluation of our therapeutic cancer vaccine UV1 across key indications. Our UV1-103 study in the U.S. continues to demonstrate encouraging and lasting patient survival, a direct measure of clinical benefit in...
Nasdaq GlobeNewswire
22/08/2023

Kanazawa University research: Brain cancer linked to nuclear pore alterations

The protein p53 is crucial in cancer prevention. The corresponding gene TP53 encodes proteins that prevent mutations of the genome and is the most frequently mutated gene in human cancers. Gaining insights into how p53 inactivation happens is crucial for understanding tumorigenesis in general and glioblastoma in particular. The protein p53 is crucial in cancer prevention. The corresponding gene TP53 encodes proteins that prevent mutations of the genome and is the most frequently mutated gene…
PR Newswire
22/08/2023

Dr. Christian Brander and Dr. Mala Maini Join World-class Scientific Advisory…

Christian Brander, Ph.D., is a leading expert on T cell responses to viral infections and brings an important blend of academic and biotech experience.Mala Maini, MD, Ph.D., is a professor of viral immunology at University College London with key expertise in adaptive immunity to hepatitis B, liver cancer, and SARS-CoV-2. Together with the other distinguished vaccine development experts on the company's scientific advisory board, they will support AstriVax in advancing its innovative...
Nasdaq GlobeNewswire
22/08/2023

Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of…

Key Takeaways from the Medical Second Opinion Market Report Key Takeaways from the Medical Second Opinion Market Report To read more about the latest highlights related to the medical second opinion market, get a snapshot of the key highlights entailed in theGlobal Medical Second Opinion Market Report Medical Second Opinion Overview A medical second opinion is a valuable resource that empowers patients to make informed decisions about their health. It involves seeking input...
PR Newswire
21/08/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...
Nasdaq GlobeNewswire
21/08/2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – August21 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on August 18,...
Nasdaq GlobeNewswire
21/08/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd , Denmark, 21August 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023...
Nasdaq GlobeNewswire
21/08/2023
Altri  Comunicati